Journal
HEPATOLOGY INTERNATIONAL
Volume 11, Issue 4, Pages 374-383Publisher
SPRINGER
DOI: 10.1007/s12072-017-9805-2
Keywords
Hepatitis C virus; Immune response; Antiviral treatment; Direct-acting antivirals
Categories
Funding
- National Natural Science Foundation of China [81601731]
Ask authors/readers for more resources
Hepatitis C virus (HCV) infects more than 170 million people worldwide and is the main cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Although the newly developed direct-acting antivirals (DAAs) have transformed the treatment of HCV infection, controlling HCV infection on a global scale remains a challenge because of the high cost, low resistance barrier of DAAs and lack of HCV vaccine. The host immune responses associated with HCV infection, especially HCV-specific T cellular immunity, determine the outcome of HCV infection: either acute or chronic infection. It is important to fully interpret the immunopathogenesis of HCV infection and consequently to exploit effective strategies to eliminate HCV. Here, we review the current progress in HCV immunology, which will deepen our understanding of the spectrum of HCV infection and immunity in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available